ArticlePediatric nephrology (Berlin, Germany)2022
Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 26 citations in OpenAlex.
- The efficacy and safety of rituximab monotherapy in the new onset pediatric idiopathic nephrotic syndrome: a randomized controlled clinical trial.Renal failure · 2025Trial
- Evaluation of the comparative efficacy and safety of obinutuzumab and other follow-up strategies after rituximab failure in refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- B cell depletion with rituximab in children with steroid-sensitive nephrotic syndrome: does depletion duration change outcome?Pediatric nephrology (Berlin, Germany) · 2026Article
- Clinical significance of anti-rituximab antibody status before rituximab administration in children with frequently relapsing or steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Anti-rituximab antibodies: implications for clinical outcomes and safety in pediatric idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- The impact of anti-rituximab antibodies on rituximab efficacy in children with frequently relapsing or steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies.Pediatric nephrology (Berlin, Germany) · 2026Article
- Nephrotic syndrome in children: A review.Medicine · 2026Review
- Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study.Drug design, development and therapy · 2026Article
- Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review.Frontiers in immunology · 2026Review
- Article
- Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.Biomedicines · 2025Review
- Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome.World journal of pediatrics : WJP · 2025Review
- Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy.Kidney international reports · 2025Article
- The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease.Clinical kidney journal · 2025Review
- Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.Kidney international reports · 2025Article
- Efficacy and safety of rituximab in children with steroid-dependent or frequently relapsing nephrotic syndrome: a meta-analysis of randomized controlled trials.Archives of medical science : AMS · 2025Review
- Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review.Pediatric nephrology (Berlin, Germany) · 2024Review
- Case report: Effective treatment of rituximab-resistant minimal change disease with obinutuzumab in an adult.Frontiers in immunology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab is a chimeric anti-CD20 monoclonal antibody that induces sustained remission in children with steroid-dependent nephrotic syndrome. However, there is no consensus on the optimal regimen and monitoring of rituximab. In other autoimmune diseases, anti-rituximab antibodies (ARA) have been reported in 10-40% of patients, but their clinical relevance remains unclear. In nephrotic syndrome, data are scarce.
methodsWe report a single-center retrospective study with immuno- and pharmacological monitoring of rituximab treatment in children with frequent relapsing (FR) or steroid-dependent nephrotic syndrome (SDNS). We analyzed the monthly monitoring of 24 children, receiving a dose of rituximab (375 mg/m
resultsARA were detected in 7/24 patients (29%), sometimes after the first infusion of rituximab. ARA were present at baseline in two patients previously treated with rituximab. Both displayed no B-cell depletion. ARA were also reported in 5/22 patients during follow-up, with antibodies always detected in the first month following B-cell recovery. An incomplete CD19+CD20- B-cell depletion at M1 (5-25/mm
conclusionsThis study shows that ARA are frequent in children with FR/SDNS and that close immuno- and pharmacological monitoring may help personalizing rituximab treatment in patients needing repeated injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.